Twenty-four hour growth hormone secretion in a patient with Werner's syndrome.
OBJECTIVE
To assess the 24-h endogenous secretory growth hormone (GH) profile and serum insulin-like growth factor-I (IGF-I) response to exogenous recombinant human growth hormone (rhGH) in a patient with Werner's syndrome.


METHODS
Blood sampling every 20 min for 24 h followed by three daily injections of growth hormone.


METHODS
General Clinical Research Center.


METHODS
Single patient with Werner's syndrome.


METHODS
Serum GH and IGF-I.


RESULTS
Growth hormone pulses were absent during the 24-h monitoring period. Likewise, integrated GH concentrations were very low at 0.25 mu min/mL, and no peaks occurred after sleep onset. Following single daily administration of rhGH, serum GH and IGF-I rose.


CONCLUSIONS
Our findings support previous but less extensive studies suggesting patients with Werner's syndrome have reduced growth hormone levels. Preliminary investigations using rhGH in patients with Werner's syndrome should be considered.
Rubin
C D
CD
Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas 75235-8889, USA. crubin@mednet.swmed.edu
Reed
B
B
D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D014898:Werner Syndrome / Q000378:metabolism*
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone